Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 18/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1702988 | 1.00 | MEN1 (0.45) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Iodide SCHEMBL1702855 | 1.00 | MEN1 (0.45) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Iodide SCHEMBL1703534 | 1.00 | MEN1 (0.45) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Iodide SCHEMBL3408657 | 0.94 | MEN1 (0.46) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL3402249 | 0.87 | FDPS (0.41) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL3402245 | 0.87 | MEN1 (0.37) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL1219617 | 0.85 | — | — | |
| SCHEMBL1219120 | 0.85 | MEN1 (0.43) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL21837196 | 0.84 | MEN1 (0.35) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL19475616 | 0.84 | FDPS (0.39) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932316-B2 | Imidazolium salts having liquid crystal characteristics, useful as electrolytes | DAUNIA SOLAR CELL S.R.L. (IT) | 2018-04-03 | — | — | US | disclosed |
| EP-2440532-B1 | Imidazolium salts having liquid crystal characteristics, useful as electrolytes | DAUNIA SOLAR CELL S R L (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-20120135316-A1 | NEW IMIDAZOLIUM SALTS HAVING LIQUID CRYSTAL CHARACTERISTICS, USEFUL AS ELECTROLYTES | DAUNIA SOLAR CELL S.R.L. (IT) | 2012-05-31 | — | — | US | disclosed |
| EP-2261217-A1 | Imidazolium salts having liquid crystal characteristics, useful as electrolytes | Politecnico di Milano (IT) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135316-A1 | NEW IMIDAZOLIUM SALTS HAVING LIQUID CRYSTAL CHARACTERISTICS, USEFUL AS ELECTROLYTES | KCNH2, KCNH3, HCN2 | MEN1 564/4885HSP90AA1 4662/4885KMT2A 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.